PEOPLEBIO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,770 KRW | +4.33% |
|
+2.21% | -9.92% |
| 2023 | PeopleBio, Inc. announced that it has received KRW 5.399992647 billion in funding | CI |
| 2023 | Peoplebio to Raise 5.4 Billion Won From Shares Issuance | MT |
| Sales 2022 | 4.44B 3.24M | Sales 2023 | 4.45B 3.25M | Capitalization | 64.67B 47.21M |
|---|---|---|---|---|---|
| Net income 2022 | -14.3B -10.44M | Net income 2023 | -16.04B -11.71M | EV / Sales 2022 | 40.3 x |
| Net cash position 2022 | 6.31B 4.61M | Net cash position 2023 | 2.69B 1.96M | EV / Sales 2023 | 13.9 x |
| P/E ratio 2022 |
-13.5
x | P/E ratio 2023 |
-3.18
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.76% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.33% | ||
| 1 week | +2.21% | ||
| Current month | -10.65% | ||
| 1 month | -7.97% | ||
| 3 months | -19.59% | ||
| 6 months | -44.10% | ||
| Current year | -9.92% |
1 week
2 610.00
2 780.00
1 month
2 610.003 215.00
Current year
2 610.004 455.00
1 year
2 610.0011 508.33
3 years
2 610.0026 583.33
5 years
2 610.0036 750.00
10 years
2 610.0036 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Min Kang
FOU | Founder | 52 | 02-09-08 |
Dae-Won Cho
DFI | Director of Finance/CFO | 51 | 02-09-08 |
Sang-Chul Ahn
AUD | Comptroller/Controller/Auditor | 51 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Min Kang
FOU | Founder | 52 | 02-09-08 |
Sung-Yoon Hwang
BRD | Director/Board Member | 63 | 18-11-30 |
Dae-Won Cho
DFI | Director of Finance/CFO | 51 | 02-09-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 2,770 | +4.33% | 45,298 |
| 24-04-22 | 2,655 | +0.19% | 28,801 |
| 24-04-19 | 2,650 | -2.21% | 45,688 |
| 24-04-18 | 2,710 | +0.37% | 36,771 |
| 24-04-17 | 2,700 | -0.37% | 73,366 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
PeopleBio Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of medical supplies. The Company's main products include oligomerized beta-amyloid (OAβ) test systems, and others. The Companyâs multimer detection system (MDS) is sandwich assay using capturing antibodies and epitope-overlapping detection antibodies for the detection of only oligomers or multimers from monomers in protein-misfolding diseases. The Company sells its products in domestic and overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.92% | 42.44M | |
| +0.80% | 12.82B | |
| -12.75% | 7.4B | |
| +2.81% | 5.47B | |
| -1.37% | 4.51B | |
| +3.89% | 4.42B | |
| -50.71% | 3.29B | |
| +9.29% | 2.66B | |
| -15.10% | 2.07B | |
| -2.82% | 1.68B |
- Stock Market
- Equities
- A304840 Stock
